CY1110354T1 - Αναστολεις της μορφης μεταλλακτη του κιτ - Google Patents

Αναστολεις της μορφης μεταλλακτη του κιτ

Info

Publication number
CY1110354T1
CY1110354T1 CY20091100748T CY091100748T CY1110354T1 CY 1110354 T1 CY1110354 T1 CY 1110354T1 CY 20091100748 T CY20091100748 T CY 20091100748T CY 091100748 T CY091100748 T CY 091100748T CY 1110354 T1 CY1110354 T1 CY 1110354T1
Authority
CY
Cyprus
Prior art keywords
kit
suspensions
exchange format
kit exchange
mutant
Prior art date
Application number
CY20091100748T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1110354T1 publication Critical patent/CY1110354T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη θεραπεία ασθενειών εξαρτώμενων από KIT που χαρακτηρίζονται από μία μορφή μεταλλάκτη KIT όπου ο μεταλλάκτης KIT προσδιορίζεται και χορηγείται ένας κατάλληλος αναστολέας του μεταλλάκτη KIT που επιλέγεται από μιδοσταουρίνη, βαταλανίβη και χορηγείται η ένωση Α.
CY20091100748T 2003-11-18 2009-07-14 Αναστολεις της μορφης μεταλλακτη του κιτ CY1110354T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
EP04818795A EP1686997B1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
CY1110354T1 true CY1110354T1 (el) 2015-04-29

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100748T CY1110354T1 (el) 2003-11-18 2009-07-14 Αναστολεις της μορφης μεταλλακτη του κιτ

Country Status (28)

Country Link
US (3) US8017621B2 (el)
EP (2) EP1686997B1 (el)
JP (3) JP4762150B2 (el)
KR (1) KR101153647B1 (el)
CN (3) CN102274230B (el)
AT (1) ATE428426T1 (el)
AU (1) AU2004290902B2 (el)
BR (1) BRPI0416680A (el)
CA (1) CA2546189C (el)
CY (1) CY1110354T1 (el)
DE (1) DE602004020654D1 (el)
DK (1) DK1686997T3 (el)
ES (1) ES2324917T3 (el)
HK (1) HK1093680A1 (el)
HR (1) HRP20090390T1 (el)
IL (2) IL175578A (el)
MA (1) MA28176A1 (el)
MX (1) MXPA06005598A (el)
NO (1) NO20062694L (el)
NZ (1) NZ547195A (el)
PL (1) PL1686997T3 (el)
PT (1) PT1686997E (el)
RU (2) RU2405553C1 (el)
SG (1) SG139747A1 (el)
SI (1) SI1686997T1 (el)
TN (1) TNSN06138A1 (el)
WO (1) WO2005049032A1 (el)
ZA (1) ZA200603905B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
NZ547195A (en) 2003-11-18 2010-06-25 Novartis Ag Inhibitors of the mutant form of kit
MX2007002415A (es) * 2004-08-31 2007-04-23 Novartis Ag Uso de midostaurina para el tratamiento de tumores estromales gastrointestinales.
KR101376875B1 (ko) 2005-05-02 2014-03-27 노파르티스 아게 전신 비만세포증의 치료를 위한 피리미딜아미노벤즈아미드유도체의 용도
JP5154408B2 (ja) * 2005-05-02 2013-02-27 ノバルティス アーゲー 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR101351682B1 (ko) * 2005-07-20 2014-01-14 피터 발렌트 전신 비만세포증 치료용 조성물
JP2009518358A (ja) * 2005-12-06 2009-05-07 ノバルティス アクチエンゲゼルシャフト 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
PT2237783E (pt) * 2008-01-23 2014-12-23 Novartis Ag Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib
WO2015082887A2 (en) * 2013-12-02 2015-06-11 Bergenbio As Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (el) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
WO1998055152A1 (en) 1997-06-06 1998-12-10 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2309639C (en) 1997-11-13 2010-03-23 John C. Houck Small peptides and methods for treatment of asthma and inflammation
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
CA2452171A1 (en) 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
JP2005519610A (ja) * 2002-03-13 2005-07-07 エフ．ホフマン−ラ　ロシュ　アーゲー 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
AU2004273605B2 (en) * 2003-09-19 2008-07-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
NZ547195A (en) 2003-11-18 2010-06-25 Novartis Ag Inhibitors of the mutant form of kit
KR101376875B1 (ko) 2005-05-02 2014-03-27 노파르티스 아게 전신 비만세포증의 치료를 위한 피리미딜아미노벤즈아미드유도체의 용도
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
RU2009110449A (ru) 2010-09-27
RU2362562C2 (ru) 2009-07-27
AU2004290902B2 (en) 2008-09-25
MA28176A1 (fr) 2006-09-01
RU2006121447A (ru) 2008-01-10
CN102274230A (zh) 2011-12-14
ATE428426T1 (de) 2009-05-15
JP2007511567A (ja) 2007-05-10
US20120157441A1 (en) 2012-06-21
DK1686997T3 (da) 2009-07-27
SI1686997T1 (sl) 2009-08-31
PL1686997T3 (pl) 2009-09-30
CN102274230B (zh) 2015-07-01
PT1686997E (pt) 2009-07-17
BRPI0416680A (pt) 2007-02-13
MXPA06005598A (es) 2006-08-11
HK1093680A1 (en) 2007-03-09
IL175578A0 (en) 2008-04-13
TNSN06138A1 (fr) 2007-11-15
US8124611B2 (en) 2012-02-28
US20100179179A1 (en) 2010-07-15
HRP20090390T1 (hr) 2009-08-31
KR101153647B1 (ko) 2012-06-18
JP2011121973A (ja) 2011-06-23
WO2005049032A1 (en) 2005-06-02
JP2013241438A (ja) 2013-12-05
DE602004020654D1 (de) 2009-05-28
CN101693031A (zh) 2010-04-14
NO20062694L (no) 2006-06-12
NZ547195A (en) 2010-06-25
KR20060101761A (ko) 2006-09-26
ZA200603905B (en) 2008-11-26
EP1686997B1 (en) 2009-04-15
IL229124A0 (en) 2013-12-31
SG139747A1 (en) 2008-02-29
RU2405553C1 (ru) 2010-12-10
CN1882344A (zh) 2006-12-20
CA2546189C (en) 2013-04-23
JP4762150B2 (ja) 2011-08-31
IL175578A (en) 2013-10-31
ES2324917T3 (es) 2009-08-19
AU2004290902A1 (en) 2005-06-02
EP1917965A1 (en) 2008-05-07
EP1686997A1 (en) 2006-08-09
US20070213317A1 (en) 2007-09-13
CA2546189A1 (en) 2005-06-02
US8017621B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
CY1110354T1 (el) Αναστολεις της μορφης μεταλλακτη του κιτ
NO20041452L (no) 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer.
ECSP055844A (es) Nuevos compuestos triciclicos
NO20050063L (no) 2-heteroaryl karboksamider
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
DK1895017T3 (da) Anvendelse af A33-antigener og JAM-IT
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
EA200100515A3 (ru) Диазепиноиндолы для лечения хронического обструктивного заболевания легких
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
DE60308913D1 (de) Gemeinsame optimierung von vor- und nach- filterkoeffizienten
NO20053247D0 (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.
DK1670309T3 (da) Transgenetiske dyr med større lidelser i forbindelse med Alzheimers sygdom
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
HN2001200000A (es) Suspension de ziprasidona
SE0101257D0 (sv) Treatment of whiplash associated disorder
MXPA04003938A (es) Compuestos retinoides heterociclicos.
HN2001000126A (es) Derivados de 3-azabiciclo (3.1.0) hexano utiles en terapia
HN2002000006A (es) Utilizacion de cromanos
HN2003000228A (es) Derivados benzufurano y benzotiofeno utiles en el tratamiento de desordenes hiper - proliferativos